How is vertical integration by Chinese pig farming giants reshaping ceftiofur demand and pricing?

How is vertical integration by Chinese pig farming giants reshaping ceftiofur demand and pricing?
Muyuan's push into veterinary drugs is a structural shift for ceftiofur. Its joint venture Henan Lianmu, with Federal Pharmaceutical, will produce ceftiofur sodium injections and is set to start commercial output in May 2025, targeting 300 million sterile powder injections annually. Muyuan holds 40% of this venture, and also co-owns Zhongmu Muyuan with China Animal Husbandry Group. This captive demand channel means a significant portion of ceftiofur API consumption will move from open market purchases to internal or contracted supply. For independent API makers, this reduces addressable demand and may force them to compete more aggressively on price for remaining third-party buyers. Conversely, it creates opportunities for API suppliers who can secure long-term contracts with these integrators. The trend mirrors similar moves by Wen's, Dabeinong, and other top hog producers, suggesting ceftiofur demand will become more concentrated and predictable, potentially stabilizing prices at lower but more consistent levels.